Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.58 |
| ▸ | ELOVL1 | Q9BW60 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.56 |
| ▸ | MGLL | Q99685 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2829180 | 0.92 | MAPT (0.60) | MAPTKMT2ANPC1POLBSMN1; SMN2 | |
| SCHEMBL2826777 | 0.92 | NPSR1 (0.66) | MAPTKMT2ANPC1POLBSMN1; SMN2 | |
| SCHEMBL2827972 | 0.92 | MAPT (0.59) | MAPTKMT2ANPC1POLBSMN1; SMN2 | |
| SCHEMBL2831060 | 0.89 | TRPA1 (0.58) | MAPTKMT2ANPC1POLBSMN1; SMN2 | |
| SCHEMBL2827630 | 0.89 | SMN1; SMN2 (0.59) | MAPTKMT2ANPC1POLBSMN1; SMN2 | |
| SCHEMBL2830760 | 0.89 | ABL1 (0.56) | MAPTKMT2ANPC1POLBSMN1; SMN2 | |
| SCHEMBL2830357 | 0.89 | TRPA1 (0.58) | MAPTKMT2ANPC1POLBSMN1; SMN2 | |
| SCHEMBL2827614 | 0.89 | HDAC1 (0.56) | MAPTKMT2ANPC1POLBSMN1; SMN2 | |
| SCHEMBL1037761 | 0.87 | KDM4E (0.62) | MAPTKMT2ANPC1POLBSMN1; SMN2 | |
| SCHEMBL2825667 | 0.87 | SMN1; SMN2 (0.63) | MAPTKMT2ANPC1SMN1; SMN2ELOVL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1948650-B1 | 2-(BENZIMIDAZOL-1-YL)-N-(4-PHENYLTHIAZOL-2-YL) ACETAMIDE DERIVATIVES USEFUL IN TREATMENT OF TRPV1 RELATED DISORDERS | ORGANON NV (NL) | 2010-05-26 | — | — | EP | claimed |
| US-20100099722-A1 | 2-(BENZIMIDAZOL-1-YL)-N-(4-PHENYLTHIAZOL-2-YL) ACETAMIDE DERIVATIVES | MSD OSS B.V. (NL) | 2010-04-22 | — | — | US | claimed |
| EP-1948650-A1 | 2-(BENZIMIDAZOL-1-YL)-N-(4-PHENYLTHIAZOL-2-YL) ACETAMIDE DERIVATIVES USEFUL IN TREATMENT OF TRPV1 RELATED DISORDERS | N.V. Organon (NL) | 2008-07-30 | — | — | EP | claimed |
| WO-2007054474-A1 | 2-(BENZIMIDAZOL-1-YL)-N-(4-PHENYLTHIAZOL-2-YL) ACETAMIDE DERIVATIVES USEFUL IN TREATMENT OF TRPV1 RELATED DISORDERS | N.V. ORGANON (NL) | 2007-05-18 | — | — | WO | claimed |
| US-20070105920-A1 | 2-(Benzimidazol-1-Yl)-N-(4-phenylthiazol-2-yl) acetamide derivatives | AKZO NOBEL N.V. (NL) | 2007-05-10 | — | — | US | claimed |
| US-20100234454-A1 | TREATMENT OF CNIDARIA INTOXICATION | KATHOLIEKE UNIVERSITEIT LEUVEN K.U. LEUVEN R&D (BE) | 2010-09-16 | — | — | US | disclosed |
| EP-1948650-B1 | 2-(BENZIMIDAZOL-1-YL)-N-(4-PHENYLTHIAZOL-2-YL) ACETAMIDE DERIVATIVES USEFUL IN TREATMENT OF TRPV1 RELATED DISORDERS | ORGANON NV (NL) | 2010-05-26 | — | — | EP | disclosed |
| US-20100099722-A1 | 2-(BENZIMIDAZOL-1-YL)-N-(4-PHENYLTHIAZOL-2-YL) ACETAMIDE DERIVATIVES | MSD OSS B.V. (NL) | 2010-04-22 | — | — | US | disclosed |
| US-20100099722-A1 | 2-(BENZIMIDAZOL-1-YL)-N-(4-PHENYLTHIAZOL-2-YL) ACETAMIDE DERIVATIVES | MSD OSS B.V. (NL) | 2010-04-22 | — | — | US | disclosed |
| EP-2034979-A2 | TREATMENT OF CNIDARIA INTOXICATION WITH VANILLOID RECEPTOR ANTAGONISTS | Katholieke Universiteit Leuven (BE) | 2009-03-18 | — | — | EP | disclosed |
| CN-101351463-A | 2-(benzimidazol-1-yl)-n-(4-phenylthiazol-2-yl) acetamide derivatives useful in treatment of TRPV1 related disorders | ORGANON NV (NL) | 2009-01-21 | — | — | CN | disclosed |
| CN-101351463-A | 2-(benzimidazol-1-yl)-n-(4-phenylthiazol-2-yl) acetamide derivatives useful in treatment of TRPV1 related disorders | ORGANON NV (NL) | 2009-01-21 | — | — | CN | disclosed |
| EP-1948650-A1 | 2-(BENZIMIDAZOL-1-YL)-N-(4-PHENYLTHIAZOL-2-YL) ACETAMIDE DERIVATIVES USEFUL IN TREATMENT OF TRPV1 RELATED DISORDERS | N.V. Organon (NL) | 2008-07-30 | — | — | EP | disclosed |
| EP-1948650-A1 | 2-(BENZIMIDAZOL-1-YL)-N-(4-PHENYLTHIAZOL-2-YL) ACETAMIDE DERIVATIVES USEFUL IN TREATMENT OF TRPV1 RELATED DISORDERS | N.V. Organon (NL) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007140551-A2 | TREATMENT OF CNIDARIA INTOXICATION WITH VANILLOID RECEPTOR ANTAGONISTS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2007-12-13 | — | — | WO | disclosed |
| WO-2007054474-A1 | 2-(BENZIMIDAZOL-1-YL)-N-(4-PHENYLTHIAZOL-2-YL) ACETAMIDE DERIVATIVES USEFUL IN TREATMENT OF TRPV1 RELATED DISORDERS | N.V. ORGANON (NL) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007054474-A1 | 2-(BENZIMIDAZOL-1-YL)-N-(4-PHENYLTHIAZOL-2-YL) ACETAMIDE DERIVATIVES USEFUL IN TREATMENT OF TRPV1 RELATED DISORDERS | N.V. ORGANON (NL) | 2007-05-18 | — | — | WO | disclosed |
| US-20070105920-A1 | 2-(Benzimidazol-1-Yl)-N-(4-phenylthiazol-2-yl) acetamide derivatives | AKZO NOBEL N.V. (NL) | 2007-05-10 | — | — | US | disclosed |
| US-20070105920-A1 | 2-(Benzimidazol-1-Yl)-N-(4-phenylthiazol-2-yl) acetamide derivatives | AKZO NOBEL N.V. (NL) | 2007-05-10 | — | — | US | disclosed |
| US-20070105920-A1 | 2-(Benzimidazol-1-Yl)-N-(4-phenylthiazol-2-yl) acetamide derivatives | AKZO NOBEL N.V. (NL) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105920-A1 | 2-(Benzimidazol-1-Yl)-N-(4-phenylthiazol-2-yl) acetamide derivatives | TRPV1, TRPV3, TRPV4 | MAPT 2205/4885KMT2A 3123/4885NPC1 372/4885 |
| US-20100099722-A1 | 2-(BENZIMIDAZOL-1-YL)-N-(4-PHENYLTHIAZOL-2-YL) ACETAMIDE DERIVATIVES | TRPV1, TRPV3, TRPA1 | MAPT 2185/4885KMT2A 3057/4885NPC1 401/4885 |
| US-20100234454-A1 | TREATMENT OF CNIDARIA INTOXICATION | CNR1, CNR2, AVPR1A | MAPT 4876/4885KMT2A 1894/4885NPC1 1678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.